CAS 136236-51-6|Rasagiline

Introduction：Basic information about CAS 136236-51-6|Rasagiline, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Rasagiline BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Customs
6. Synonyms

Common Name	Rasagiline
CAS Number	136236-51-6	Molecular Weight	171.238
Density	1.1±0.1 g/cm3	Boiling Point	305.5±30.0 °C at 760 mmHg
Molecular Formula	C₁₂H₁₃N	Melting Point	35-41°C
MSDS	/	Flash Point	146.8±20.0 °C

Names

Name	Rasagiline
Synonym	More Synonyms

Rasagiline BiologicalActivity

Description	Rasagiline(AGN1135;TVP1012) is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease. Target: Monoamine Oxidase (MAO)-BRasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug. Rasagiline is effective as monotherapy or adjunct to L-Dopa for patients with early and late Parkinson's disease (PD) [1]. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established [2]. Rasagiline has been found to be well tolerated and effective in the treatment of early PD and as adjunctive treatment in motor fluctuations. Whether rasagiline is associated with clinically significant neuroprotection (ie, disease modification) in PD is the subject of ongoing clinical trials [3].
Related Catalog	Signaling Pathways >>Neuronal Signaling >>Monoamine OxidaseResearch Areas >>Neurological Disease
References	[1]. Leegwater-Kim, J. and E. Bortan, The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging, 2010. 5: p. 149-56. [2]. Weinreb, O., et al., Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol, 2010. 92(3): p. 330-44. [3]. Chen, J.J., D.M. Swope, and K. Dashtipour, Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther, 2007. 29(9): p. 1825-49.

Description

Rasagiline(AGN1135;TVP1012) is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease. Target: Monoamine Oxidase (MAO)-BRasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug. Rasagiline is effective as monotherapy or adjunct to L-Dopa for patients with early and late Parkinson's disease (PD) [1]. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established [2]. Rasagiline has been found to be well tolerated and effective in the treatment of early PD and as adjunctive treatment in motor fluctuations. Whether rasagiline is associated with clinically significant neuroprotection (ie, disease modification) in PD is the subject of ongoing clinical trials [3].

Related Catalog

Signaling Pathways >>Neuronal Signaling >>Monoamine OxidaseResearch Areas >>Neurological Disease

References

[1]. Leegwater-Kim, J. and E. Bortan, The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging, 2010. 5: p. 149-56.

[2]. Weinreb, O., et al., Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol, 2010. 92(3): p. 330-44.

[3]. Chen, J.J., D.M. Swope, and K. Dashtipour, Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther, 2007. 29(9): p. 1825-49.

Chemical & Physical Properties

Density	1.1±0.1 g/cm3
Boiling Point	305.5±30.0 °C at 760 mmHg
Melting Point	35-41°C
Molecular Formula	C₁₂H₁₃N
Molecular Weight	171.238
Flash Point	146.8±20.0 °C
Exact Mass	171.104797
PSA	12.03000
LogP	2.27
Vapour Pressure	0.0±0.6 mmHg at 25°C
Index of Refraction	1.577
InChIKey	RUOKEQAAGRXIBM-GFCCVEGCSA-N
SMILES	C#CCNC1CCc2ccccc21
Storage condition	2-8°C

Safety Information

Hazard Codes	Xi
HS Code	2921499090

Customs

HS Code	2921499090
Summary	2921499090 other aromatic monoamines and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0%

Synonyms

(1R)-2,3-Dihydro-N-2-propynyl-1H-inden-1-amine

(1R)-N-(Prop-2-yn-1-yl)indan-1-amine

(1R)-N-(2-Propyn-1-yl)-1-indanamine

(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine

Rasagiline

1H-Inden-1-amine, 2,3-dihydro-N-2-propyn-1-yl-, (1R)-

(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine

(R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine

Recommended......